Proteins > Lysine-specific histone demethylase 1A
Page last updated: 2024-08-07 18:26:51
Lysine-specific histone demethylase 1A
A lysine-specific histone demethylase 1A that is encoded in the genome of human. [PRO:DNx, UniProtKB:O60341]
Synonyms
EC 1.14.99.66;
BRAF35-HDAC complex protein BHC110;
Flavin-containing amine oxidase domain-containing protein 2;
[histone H3]-dimethyl-L-lysine(4) FAD-dependent demethylase 1A
Research
Bioassay Publications (46)
Timeframe | Studies on this Protein(%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (2.17) | 29.6817 |
2010's | 30 (65.22) | 24.3611 |
2020's | 15 (32.61) | 2.80 |
Compounds (48)
Drugs with Inhibition Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
berberine | Homo sapiens (human) | IC50 | 6.9700 | 1 | 1 |
phenelzine | Homo sapiens (human) | Ki | 11.7000 | 4 | 4 |
raloxifene | Homo sapiens (human) | IC50 | 2.0800 | 1 | 1 |
vorinostat | Homo sapiens (human) | IC50 | 100.0000 | 2 | 2 |
2-phenylcyclopropan-1-amine | Homo sapiens (human) | IC50 | 65.1025 | 4 | 4 |
hesperidin | Homo sapiens (human) | IC50 | 19.1600 | 1 | 1 |
palmatine | Homo sapiens (human) | IC50 | 12.2300 | 1 | 1 |
tranylcypromine | Homo sapiens (human) | IC50 | 31.7023 | 13 | 13 |
tranylcypromine | Homo sapiens (human) | Ki | 208.2200 | 5 | 5 |
(1S,2R)-tranylcypromine | Homo sapiens (human) | IC50 | 16.4700 | 7 | 7 |
(1S,2R)-tranylcypromine | Homo sapiens (human) | Ki | 159.5333 | 2 | 3 |
dehydrocorydalin | Homo sapiens (human) | IC50 | 2.4400 | 1 | 1 |
baicalin | Homo sapiens (human) | IC50 | 3.1900 | 3 | 3 |
hesperetin | Homo sapiens (human) | IC50 | 78.7600 | 1 | 1 |
columbamine | Homo sapiens (human) | IC50 | 0.4700 | 2 | 2 |
jatrorrhizine | Homo sapiens (human) | IC50 | 1.5500 | 1 | 1 |
higenamine | Homo sapiens (human) | IC50 | 1.4700 | 1 | 1 |
tanshinone | Homo sapiens (human) | IC50 | 16.4500 | 2 | 2 |
cryptotanshinone | Homo sapiens (human) | IC50 | 9.0200 | 1 | 1 |
epiberberine | Homo sapiens (human) | IC50 | 0.1400 | 4 | 4 |
erlotinib | Homo sapiens (human) | IC50 | 35.8000 | 1 | 1 |
resveratrol | Homo sapiens (human) | IC50 | 12.6000 | 2 | 2 |
curcumin | Homo sapiens (human) | IC50 | 9.6000 | 1 | 1 |
capsaicin | Homo sapiens (human) | IC50 | 0.6000 | 3 | 3 |
(1R,2S)-tranylcypromine hydrochloride | Homo sapiens (human) | IC50 | 14.9500 | 2 | 2 |
N5-(2-chloro-6-phenoxybenzyl)-1H-1,2,4-triazole-3,5-diamine | Homo sapiens (human) | IC50 | 1.1700 | 4 | 4 |
N5-(2-chloro-6-phenoxybenzyl)-1H-1,2,4-triazole-3,5-diamine | Homo sapiens (human) | Ki | 2.2000 | 1 | 1 |
mdl 72527 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
wogonoside | Homo sapiens (human) | IC50 | 2.9800 | 1 | 1 |
quercetin | Homo sapiens (human) | IC50 | 1.2600 | 1 | 1 |
biochanin a | Homo sapiens (human) | IC50 | 2.9500 | 3 | 3 |
quercetin 3-o-glucopyranoside | Homo sapiens (human) | IC50 | 0.9500 | 1 | 1 |
quercetin 3-o-glucopyranoside | Homo sapiens (human) | Ki | 1.0000 | 1 | 1 |
rutin | Homo sapiens (human) | IC50 | 2.1600 | 1 | 1 |
baicalein | Homo sapiens (human) | IC50 | 12.5000 | 1 | 1 |
diosmetin | Homo sapiens (human) | IC50 | 27.9000 | 1 | 1 |
diosmin | Homo sapiens (human) | IC50 | 10.1400 | 1 | 1 |
mangostin | Homo sapiens (human) | IC50 | 2.8100 | 1 | 1 |
wogonin | Homo sapiens (human) | IC50 | 8.8700 | 1 | 1 |
rosmarinic acid | Homo sapiens (human) | IC50 | 20.9300 | 2 | 2 |
afimoxifene | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
icaritin | Homo sapiens (human) | IC50 | 64.4900 | 1 | 1 |
icariin | Homo sapiens (human) | IC50 | 26.4400 | 1 | 1 |
baohuoside i | Homo sapiens (human) | IC50 | 16.7000 | 1 | 1 |
salvianolic acid B | Homo sapiens (human) | IC50 | 0.1100 | 2 | 2 |
Diosmetin 7-O-beta-D-glucopyranoside | Homo sapiens (human) | IC50 | 21.8300 | 1 | 1 |
Dihydrotanshinone I | Homo sapiens (human) | IC50 | 15.8500 | 2 | 2 |
N-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
1-(4-methyl-1-piperazinyl)-2-[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]ethanone | Homo sapiens (human) | IC50 | 0.0258 | 4 | 4 |
gsk2879552 | Homo sapiens (human) | IC50 | 50.6981 | 8 | 8 |
gsk2879552 | Homo sapiens (human) | Ki | 1.1365 | 3 | 3 |
osimertinib | Homo sapiens (human) | IC50 | 3.9800 | 1 | 1 |
Drugs with Activation Measurements
Drugs with Other Measurements
Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors.European journal of medicinal chemistry, , Jan-05, Volume: 125, 2017
A selective phenelzine analogue inhibitor of histone demethylase LSD1.ACS chemical biology, , Jun-20, Volume: 9, Issue:6, 2014
Lysine demethylases inhibitors.Journal of medicinal chemistry, , Dec-22, Volume: 54, Issue:24, 2011
Inhibitors of histone demethylases.Bioorganic & medicinal chemistry, , Jun-15, Volume: 19, Issue:12, 2011
Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.European journal of medicinal chemistry, , Aug-05, Volume: 220, 2021
Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.European journal of medicinal chemistry, , Nov-10, Volume: 140, 2017
Cancer-Cell-Selective Targeting by Arylcyclopropylamine-Vorinostat Conjugates.ACS medicinal chemistry letters, , Oct-13, Volume: 13, Issue:10, 2022
Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.European journal of medicinal chemistry, , Dec-01, Volume: 141, 2017
Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.European journal of medicinal chemistry, , Nov-10, Volume: 140, 2017
Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .Biochemistry, , Aug-03, Volume: 49, Issue:30, 2010
A comprehensive comparative study on LSD1 in different cancers and tumor specific LSD1 inhibitors.European journal of medicinal chemistry, , Oct-05, Volume: 240, 2022
[no title available]European journal of medicinal chemistry, , Dec-05, Volume: 225, 2021
Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.European journal of medicinal chemistry, , Jun-01, Volume: 195, 2020
[1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.European journal of medicinal chemistry, , Feb-01, Volume: 187, 2020
Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors.ACS medicinal chemistry letters, , Jun-11, Volume: 11, Issue:6, 2020
Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.Journal of medicinal chemistry, , 12-10, Volume: 63, Issue:23, 2020
Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking.Bioorganic & medicinal chemistry letters, , 02-15, Volume: 29, Issue:4, 2019
Flavone-based natural product agents as new lysine-specific demethylase 1 inhibitors exhibiting cytotoxicity against breast cancer cells in vitro.Bioorganic & medicinal chemistry, , 01-15, Volume: 27, Issue:2, 2019
Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor.Bioorganic & medicinal chemistry letters, , 03-15, Volume: 29, Issue:6, 2019
Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors.Bioorganic & medicinal chemistry letters, , 04-01, Volume: 28, Issue:6, 2018
Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.Bioorganic & medicinal chemistry letters, , 01-15, Volume: 28, Issue:2, 2018
Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.Bioorganic & medicinal chemistry, , 02-01, Volume: 26, Issue:3, 2018
3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.Journal of medicinal chemistry, , Jan-14, Volume: 59, Issue:1, 2016
Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.Journal of medicinal chemistry, , Feb-25, Volume: 59, Issue:4, 2016
Lysine demethylases inhibitors.Journal of medicinal chemistry, , Dec-22, Volume: 54, Issue:24, 2011
Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor.Bioorganic & medicinal chemistry, , Jun-15, Volume: 19, Issue:12, 2011
Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors.Bioorganic & medicinal chemistry, , Jun-15, Volume: 19, Issue:12, 2011
Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B.Bioorganic & medicinal chemistry letters, , May-15, Volume: 18, Issue:10, 2008
[no title available]Journal of medicinal chemistry, , 03-10, Volume: 65, Issue:5, 2022
Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).European journal of medicinal chemistry, , Mar-05, Volume: 231, 2022
Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.European journal of medicinal chemistry, , May-15, Volume: 194, 2020
Optimization of 5-arylidene barbiturates as potent, selective, reversible LSD1 inhibitors for the treatment of acute promyelocytic leukemia.Bioorganic & medicinal chemistry, , 09-15, Volume: 26, Issue:17, 2018
Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.European journal of medicinal chemistry, , Jan-20, Volume: 144, 2018
Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking.Chemical biology & drug design, , Volume: 85, Issue:6, 2015
Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors.Bioorganic & medicinal chemistry, , Jun-15, Volume: 19, Issue:12, 2011
Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.European journal of medicinal chemistry, , Aug-05, Volume: 220, 2021
Histone lysine specific demethylase 1 inhibitors.RSC medicinal chemistry, , Sep-01, Volume: 11, Issue:9, 2020
Flavone-based natural product agents as new lysine-specific demethylase 1 inhibitors exhibiting cytotoxicity against breast cancer cells in vitro.Bioorganic & medicinal chemistry, , 01-15, Volume: 27, Issue:2, 2019
Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).European journal of medicinal chemistry, , Mar-05, Volume: 231, 2022
A comprehensive comparative study on LSD1 in different cancers and tumor specific LSD1 inhibitors.European journal of medicinal chemistry, , Oct-05, Volume: 240, 2022
Annual review of LSD1/KDM1A inhibitors in 2020.European journal of medicinal chemistry, , Mar-15, Volume: 214, 2021
Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.European journal of medicinal chemistry, , Aug-05, Volume: 220, 2021
A comprehensive comparative study on LSD1 in different cancers and tumor specific LSD1 inhibitors.European journal of medicinal chemistry, , Oct-05, Volume: 240, 2022
Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).European journal of medicinal chemistry, , Mar-05, Volume: 231, 2022
Annual review of LSD1/KDM1A inhibitors in 2020.European journal of medicinal chemistry, , Mar-15, Volume: 214, 2021
Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.Journal of medicinal chemistry, , Jan-09, Volume: 57, Issue:1, 2014
Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration.Journal of medicinal chemistry, , Nov-14, Volume: 56, Issue:21, 2013
Dual inhibitors of LSD1 and spermine oxidase.MedChemComm, , May-01, Volume: 10, Issue:5, 2019
Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.European journal of medicinal chemistry, , Jan-20, Volume: 144, 2018
Aminotriazole and Aminotetrazole Inhibitors of LSD1 as Epigenetic Modulators.ACS medicinal chemistry letters, , Feb-11, Volume: 7, Issue:2, 2016
3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors.MedChemComm, , Volume: 5, Issue:12, 2014
Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).European journal of medicinal chemistry, , Mar-05, Volume: 231, 2022
A comprehensive comparative study on LSD1 in different cancers and tumor specific LSD1 inhibitors.European journal of medicinal chemistry, , Oct-05, Volume: 240, 2022
Annual review of LSD1/KDM1A inhibitors in 2020.European journal of medicinal chemistry, , Mar-15, Volume: 214, 2021
Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.Journal of medicinal chemistry, , 12-10, Volume: 63, Issue:23, 2020
4-Hydroxy-3-methylbenzofuran-2-carbohydrazones as novel LSD1 inhibitors.Bioorganic & medicinal chemistry letters, , 05-15, Volume: 30, Issue:10, 2020
[no title available]Journal of medicinal chemistry, , 03-10, Volume: 65, Issue:5, 2022
Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors.ACS medicinal chemistry letters, , Jun-11, Volume: 11, Issue:6, 2020
Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.Journal of medicinal chemistry, , 12-10, Volume: 63, Issue:23, 2020
Tranylcypromine and 6-trifluoroethyl thienopyrimidine hybrid as LSD1 inhibitor.Bioorganic & medicinal chemistry letters, , 03-15, Volume: 29, Issue:6, 2019
Ligand-based design, synthesis and biological evaluation of xanthine derivatives as LSD1/KDM1A inhibitors.European journal of medicinal chemistry, , Jan-15, Volume: 162, 2019
Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors.European journal of medicinal chemistry, , Jan-05, Volume: 125, 2017
[no title available]ACS medicinal chemistry letters, , Apr-13, Volume: 8, Issue:4, 2017
Recent Progress in Histone Demethylase Inhibitors.Journal of medicinal chemistry, , Feb-25, Volume: 59, Issue:4, 2016
Enables
This protein enables 21 target(s):
Target | Category | Definition |
p53 binding | molecular function | Binding to one of the p53 family of proteins. [GOC:hjd] |
chromatin binding | molecular function | Binding to chromatin, the network of fibers of DNA, protein, and sometimes RNA, that make up the chromosomes of the eukaryotic nucleus during interphase. [GOC:jl, ISBN:0198506732, PMID:20404130] |
transcription coactivator activity | molecular function | A transcription coregulator activity that activates or increases the transcription of specific gene sets via binding to a DNA-bound DNA-binding transcription factor, either on its own or as part of a complex. Coactivators often act by altering chromatin structure and modifications. For example, one class of transcription coactivators modifies chromatin structure through covalent modification of histones. A second class remodels the conformation of chromatin in an ATP-dependent fashion. A third class modulates interactions of DNA-bound DNA-binding transcription factors with other transcription coregulators. A fourth class of coactivator activity is the bridging of a DNA-binding transcription factor to the general (basal) transcription machinery. The Mediator complex, which bridges sequence-specific DNA binding transcription factors and RNA polymerase, is also a transcription coactivator. [GOC:txnOH-2018, PMID:10213677, PMID:16858867] |
protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
oxidoreductase activity | molecular function | Catalysis of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered. One substrate acts as a hydrogen or electron donor and becomes oxidized, while the other acts as hydrogen or electron acceptor and becomes reduced. [GOC:go_curators] |
enzyme binding | molecular function | Binding to an enzyme, a protein with catalytic activity. [GOC:jl] |
nuclear receptor coactivator activity | molecular function | A transcription coactivator activity that activates or increases the transcription of specific gene sets via binding to a DNA-bound nuclear receptor, either on its own or as part of a complex. Coactivators often act by altering chromatin structure and modifications. For example, one class of transcription coregulators modifies chromatin structure through covalent modification of histones. A second class remodels the conformation of chromatin in an ATP-dependent fashion. A third class modulates interactions of DNA-bound DNA-binding transcription factors with other transcription coregulators. A fourth class of coactivator activity is the bridging of a DNA-binding transcription factor to the general (basal) transcription machinery. The Mediator complex, which bridges sequence-specific DNA binding transcription factors and RNA polymerase, is also a transcription coactivator. [GOC:dph, GOC:tb] |
demethylase activity | molecular function | Catalysis of the removal of a methyl group from a substrate. [GOC:mah] |
histone demethylase activity | molecular function | Catalysis of the removal of a methyl group from a histone. [GOC:mah] |
histone H3K4 demethylase activity | molecular function | Catalysis of the removal of a methyl group from a modified lysine residue at position 4 of the histone H3 protein. [GOC:mah] |
histone H3K9 demethylase activity | molecular function | Catalysis of the removal of a methyl group from a modified lysine residue at position 9 of the histone H3 protein. [PMID:16362057] |
identical protein binding | molecular function | Binding to an identical protein or proteins. [GOC:jl] |
MRF binding | molecular function | Binding to Myogenic Regulatory Factor (MRF), a member of the basic Helix-Loop-Helix (bHLH) superfamily of transcription factors. [PMID:10966875] |
flavin adenine dinucleotide binding | molecular function | Binding to FAD, flavin-adenine dinucleotide, the coenzyme or the prosthetic group of various flavoprotein oxidoreductase enzymes, in either the oxidized form, FAD, or the reduced form, FADH2. [GOC:ai, GOC:imk, ISBN:0198506732] |
nuclear androgen receptor binding | molecular function | Binding to a nuclear androgen receptor. [GOC:ai] |
RNA polymerase II-specific DNA-binding transcription factor binding | molecular function | Binding to a sequence-specific DNA binding RNA polymerase II transcription factor, any of the factors that interact selectively and non-covalently with a specific DNA sequence in order to modulate transcription. [GOC:dph, GOC:vw] |
telomeric repeat-containing RNA binding | molecular function | Binding to long non-coding RNA molecules transcribed from subtelomeric regions in most eukaryotes. Telomeric repeat-containing RNA (TERRA) molecules consist of subtelomeric-derived sequences and G-rich telomeric repeats. [GOC:BHF, GOC:BHF_telomere, GOC:dph, GOC:jbu, PMID:20655916] |
DNA-binding transcription factor binding | molecular function | Binding to a DNA-binding transcription factor, a protein that interacts with a specific DNA sequence (sometimes referred to as a motif) within the regulatory region of a gene to modulate transcription. [GOC:txnOH-2018] |
FAD-dependent H3K4me/H3K4me3 demethylase activity | molecular function | Catalysis of the removal of a methyl group from a di- or a monomethyl-lysine residue at position 4 of the histone H3 protein. This is a flavin adenine dinucleotide (FAD)-dependent amine oxidation reaction. [PMID:22473470] |
promoter-specific chromatin binding | molecular function | Binding to a section of chromatin that is associated with gene promoter sequences of DNA. [PMID:19948729] |
transcription factor binding | molecular function | Binding to a transcription factor, a protein required to initiate or regulate transcription. [ISBN:0198506732] |
Located In
This protein is located in 3 target(s):
Target | Category | Definition |
chromosome, telomeric region | cellular component | The end of a linear chromosome, required for the integrity and maintenance of the end. A chromosome telomere usually includes a region of telomerase-encoded repeats the length of which rarely exceeds 20 bp each and that permits the formation of a telomeric loop (T-loop). The telomeric repeat region is usually preceded by a sub-telomeric region that is gene-poor but rich in repetitive elements. Some telomeres only consist of the latter part (for eg. D. melanogaster telomeres). [GOC:elh] |
nucleus | cellular component | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. [GOC:go_curators] |
nucleoplasm | cellular component | That part of the nuclear content other than the chromosomes or the nucleolus. [GOC:ma, ISBN:0124325653] |
Active In
This protein is active in 1 target(s):
Target | Category | Definition |
nucleus | cellular component | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. [GOC:go_curators] |
Part Of
This protein is part of 4 target(s):
Target | Category | Definition |
chromatin | cellular component | The ordered and organized complex of DNA, protein, and sometimes RNA, that forms the chromosome. [GOC:elh, PMID:20404130] |
transcription regulator complex | cellular component | A protein complex that is capable of associating with DNA by direct binding, or via other DNA-binding proteins or complexes, and regulating transcription. [GOC:jl] |
protein-containing complex | cellular component | A stable assembly of two or more macromolecules, i.e. proteins, nucleic acids, carbohydrates or lipids, in which at least one component is a protein and the constituent parts function together. [GOC:dos, GOC:mah] |
DNA repair complex | cellular component | A protein complex involved in DNA repair processes including direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway. [GOC:bhm, PMID:17217467, PMID:20551348, PMID:22749910, PMID:24192350] |
Involved In
This protein is involved in 26 target(s):
Target | Category | Definition |
negative regulation of transcription by RNA polymerase II | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of transcription mediated by RNA polymerase II. [GOC:go_curators, GOC:txnOH] |
positive regulation of neuroblast proliferation | biological process | Any process that activates or increases the rate of neuroblast proliferation. [GOC:dph] |
regulation of transcription by RNA polymerase II | biological process | Any process that modulates the frequency, rate or extent of transcription mediated by RNA polymerase II. [GOC:go_curators, GOC:txnOH] |
protein demethylation | biological process | The removal of a methyl group, from a protein amino acid. A methyl group is derived from methane by the removal of a hydrogen atom. [GOC:mah] |
positive regulation of epithelial to mesenchymal transition | biological process | Any process that increases the rate, frequency, or extent of epithelial to mesenchymal transition. Epithelial to mesenchymal transition is where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell. [GOC:BHF, GOC:dph, GOC:tb] |
positive regulation of neuron projection development | biological process | Any process that increases the rate, frequency or extent of neuron projection development. Neuron projection development is the process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites). [GOC:dph, GOC:tb] |
cerebral cortex development | biological process | The progression of the cerebral cortex over time from its initial formation until its mature state. The cerebral cortex is the outer layered region of the telencephalon. [GO_REF:0000021, GOC:cls, GOC:dgh, GOC:dph, GOC:jid] |
negative regulation of protein binding | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of protein binding. [GOC:mah] |
neuron maturation | biological process | A developmental process, independent of morphogenetic (shape) change, that is required for a neuron to attain its fully functional state. [GOC:dph, GOC:jl] |
negative regulation of DNA binding | biological process | Any process that stops or reduces the frequency, rate or extent of DNA binding. DNA binding is any process in which a gene product interacts selectively with DNA (deoxyribonucleic acid). [GOC:dph, GOC:jl, GOC:tb] |
negative regulation of DNA-binding transcription factor activity | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of the activity of a transcription factor, any factor involved in the initiation or regulation of transcription. [GOC:jl] |
negative regulation of DNA damage response, signal transduction by p53 class mediator | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of the cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage. [GOC:jl] |
positive regulation of cell size | biological process | Any process that increases cell size. [GOC:go_curators] |
negative regulation of DNA-templated transcription | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of cellular DNA-templated transcription. [GOC:go_curators, GOC:txnOH] |
positive regulation of transcription by RNA polymerase II | biological process | Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter. [GOC:go_curators, GOC:txnOH] |
guanine metabolic process | biological process | The chemical reactions and pathways involving guanine, 2-amino-6-hydroxypurine, a purine that is one of the five main bases found in nucleic acids and a component of a number of phosphorylated guanosine derivatives whose metabolic or regulatory functions are important. [GOC:go_curators] |
muscle cell development | biological process | The process whose specific outcome is the progression of a muscle cell over time, from its formation to the mature structure. Muscle cell development does not include the steps involved in committing an unspecified cell to the muscle cell fate. [CL:0000187, GOC:devbiol] |
regulation of androgen receptor signaling pathway | biological process | Any process that modulates the rate, frequency, or extent of the androgen receptor signaling pathway. [GOC:dph] |
response to fungicide | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a fungicide stimulus. Fungicides are chemicals used to kill fungi. [GOC:dph] |
cellular response to cAMP | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cAMP (cyclic AMP, adenosine 3',5'-cyclophosphate) stimulus. [GOC:mah] |
regulation of DNA methylation-dependent heterochromatin formation | biological process | Any process that modulates the rate, frequency, or extent of DNA methylation-dependent heterochromatin formation. [GOC:BHF] |
positive regulation of cold-induced thermogenesis | biological process | Any process that activates or increases the frequency, rate or extent of cold-induced thermogenesis. [PMID:27876809] |
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | biological process | Any process that stops, prevents or reduces the frequency, rate or extent of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator. [GOC:TermGenie, PMID:17719541] |
positive regulation of neural precursor cell proliferation | biological process | Any process that activates or increases the frequency, rate or extent of neural precursor cell proliferation. [GOC:dph, GOC:yaf] |
positive regulation of stem cell proliferation | biological process | Any process that activates or increases the frequency, rate or extent of stem cell proliferation. [GOC:dph] |
chromatin remodeling | biological process | A dynamic process of chromatin reorganization resulting in changes to chromatin structure. These changes allow DNA metabolic processes such as transcriptional regulation, DNA recombination, DNA repair, and DNA replication. [GOC:jid, GOC:vw, PMID:12042764, PMID:12697820] |